Adhikari et al. examined something most people overlook: not just what we eat, but how often we rely on fast food and how much our environment nudges us toward it. Using a U.S.-based case-control dataset, they found that individuals consuming fast food at least once per week had roughly double the odds of developing colorectal cancer compared to those who rarely or never consumed it.

Something that I found interesting is that living near fast-food restaurants didn’t increase cancer risk, but it was associated with a small increase in overall mortality among those already diagnosed. Frequency of consumption appears to be the most important factor increasing risk, reinforcing a larger pattern we continue to see: highly processed, calorie-dense diets actively shape long-term cancer outcomes.

Spada et al. take a very different approach than most nutrition studies. Instead of looking at short-term dietary patterns, they analyzed decades of data to ask a more important question: what happens when exposure accumulates over time? Using long-term population data, they found a consistent association between increased consumption of animal-based foods like meat and dairy and higher rates of both breast and prostate cancer. For prostate cancer, the signal appeared roughly 15 years later, and for breast cancer, closer to 18 years.

That lag aligns with what we understand about cancer biology. Cancer is not a disease that develops overnight. It evolves slowly, influenced by repeated exposures over years, even decades. The authors also highlight a plausible biological mechanism: animal-based foods may introduce or amplify hormone-related signaling, particularly estrogenic effects, which can influence the early stages of tumor development.

We tend to evaluate our health decisions based on short-term feedback. This study reminds us that some of the most important consequences are delayed, unfolding well beyond the window when most people stop paying attention.

This study takes a closer look at the real-world consequences of androgen deprivation therapy (ADT) and the numbers are hard to ignore. In a cohort of over 10,000 men with PCa, the 3-year fracture risk exceeded 25% even in those without a prior fracture. For men who had already fractured, that risk jumped to over 50% within three years.

A prior fracture nearly tripled the risk of another fracture, and even with bone-protective medications, the risk remained high. This suggests we’re often intervening too late. There is some benefit to treatment, with bone health agents reducing fracture risk by about 20–25%, but that reduction doesn’t fully offset the vulnerability.

All of this makes sense. ADT, when combined with newer androgen receptor pathway inhibitors, accelerates bone loss while also increasing fall risk through muscle loss and neurologic side effects. The result is a perfect storm: weaker bone combined with a higher likelihood of falling.

Salagierski et al. address a problem in PCa that doesn’t get nearly enough attention: overtreatment. In the era of widespread PSA screening, many men are diagnosed with low-risk disease that may never meaningfully impact their lifespan. Active surveillance has emerged as a way to manage disease by monitoring closely with PSA, imaging and periodic biopsies, while avoiding the immediate side effects of surgery or radiation.

In trials with up to 15–25 years of follow-up, PCa–specific mortality remains remarkably low in carefully selected patients on surveillance. In fact, men with low-risk disease (Grade Group 1) showed no prostate cancer–related deaths in one major study, and many were able to avoid treatment altogether for years and sometimes decades.

Not every PCa diagnosis requires immediate intervention. For the right patient, active surveillance offers a way to maintain quality of life without compromising long-term outcomes, because doing less, when appropriate, can be just as important as doing more.